| 3.44 0.24 (7.5%) | 05-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.43 | 1-year : | 5.18 |
| Resists | First : | 3.79 | Second : | 4.43 |
| Pivot price | 3.3 |
|||
| Supports | First : | 2.97 | Second : | 2.46 |
| MAs | MA(5) : | 3.27 |
MA(20) : | 3.3 |
| MA(100) : | 4.25  |
MA(250) : | 10.48 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32 |
D(3) : | 29 |
| RSI | RSI(14): 53.4 |
|||
| 52-week | High : | 28.92 | Low : | 2.23 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FDMT ] has closed below upper band by 31.8%. Bollinger Bands are 53.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.48 - 3.5 | 3.5 - 3.51 |
| Low: | 3.16 - 3.17 | 3.17 - 3.19 |
| Close: | 3.41 - 3.44 | 3.44 - 3.46 |
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Fri, 16 May 2025
4DMT Boosts Talent Acquisition: 31,800 RSUs Granted as Biotech Firm Accelerates Growth - Stock Titan
Fri, 09 May 2025
4D Molecular Therapeutics Reports Increased Quarterly Loss - TipRanks
Thu, 08 May 2025
4DMT Hits Milestone with Promising Clinical Trials and Strategic Focus | FDMT Stock News - GuruFocus
Thu, 08 May 2025
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Thu, 08 May 2025
4D Molecular Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView
Thu, 08 May 2025
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 3.433e+007 (%) |
| Held by Institutions | 3.8 (%) |
| Shares Short | 5,060 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.988e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -383 % |
| Return on Assets (ttm) | 7.1 % |
| Return on Equity (ttm) | -22.2 % |
| Qtrly Rev. Growth | 23000 % |
| Gross Profit (p.s.) | -17.49 |
| Sales Per Share | -11.53 |
| EBITDA (p.s.) | -5.38811e+007 |
| Qtrly Earnings Growth | -3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -153 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.3 |
| Price to Cash Flow | 0.97 |
| Dividend | 0 |
| Forward Dividend | 5.04e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|